Cargando…
COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica
Autores principales: | Cabal-Herrera, Ana Maria, Mateen, Farrah J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076662/ https://www.ncbi.nlm.nih.gov/pubmed/33904965 http://dx.doi.org/10.1007/s00415-021-10578-7 |
Ejemplares similares
-
Eculizumab in the treatment of neuromyelitis optica spectrum disorder
por: Nabizadeh, Fardin, et al.
Publicado: (2023) -
Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report
por: Digala, Lakshmi, et al.
Publicado: (2021) -
Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder
por: Özçelik, Pınar, et al.
Publicado: (2017) -
Persistent Hyperthermia in a Patient with Aquaporin-4-Antibody-Positive Neuromyelitis Optica Spectrum Disorder
por: Hsu, Chia-Lun, et al.
Publicado: (2016) -
Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies
por: Jentzer, Alexandre, et al.
Publicado: (2022)